{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:26:00Z","timestamp":1787599560139,"version":"build-2736575974"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1760","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved Inqovi (Taiho Oncology), a fixed-dose combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine, for use in combination with venetoclax (Venclexta, and generics) for oral treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are \u226575 years old or who have comorbidities that prevent use of intensive induction chemotherapy. The combination was approved in 2020 for treatment of myelodysplastic syndromes (MDS). IV decitabine or azacitidine plus oral venetoclax has been used for treatment of newly diagnosed AML for years.<\/jats:p>","DOI":"10.58347\/tml.2026.1760e","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:08:01Z","timestamp":1787598481000},"page":"e127-e128","source":"Crossref","is-referenced-by-count":0,"title":["Inqovi for Acute Myeloid Leukemia"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,8,3]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:08:01Z","timestamp":1787598481000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1760e"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":0,"journal-issue":{"issue":"1760","published-online":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1760e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}